PROTOKOLwiki
COMPOUNDS / PEPTIDE / BPC-157
PEPTIDE

BPC-157

MEDIUM RISK
BEST FOR:Recovery●●●●●●●○○○7/10
BPC-157 · BPC 157 · BODY PROTECTION COMPOUND 157 · BODY PROTECTION COMPOUND-157 · STABLE GASTRIC PENTADECAPEPTIDE BPC 157 · GASTRIC PENTADECAPEPTIDE
PeptideHealingRecoveryWound HealingAnti-inflammatoryAngiogenesis

A gastric pentadecapeptide with regenerative and cytoprotective properties; not FDA-approved and with minimal human clinical data.

ROUTE / DOSAGE
LOW250mcg
STANDARD500mcg
HIGH1000mcg
Note: Oral BPC-157 arginine salt only - standard form not orally active
CYCLE
4-6 weeks on 4 weeks off
BIOAVAILABILITY
~15% oral high SC/IM
ACTIVE DURATION
4-6h (subjective)
STORAGE
Refrigerated 2-8°C reconstituted solution stable ~30 days protect from light lyophilized powder room temp short-term
HALF-LIFE
Less than 30 minutes (plasma)
DURATION BREAKDOWN
Total4-8h
Onset30-60min
Come up30-60 min
Peak1-3h
Offset2-4h
After effects4-8h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
6 documented
Promotes musculoskeletal soft tissue healing
Enhances angiogenesis and blood vessel formation
Reduces inflammatory cytokines
Supports gastrointestinal mucosal integrity
Accelerates wound and burn healing
Promotes neuromuscular stabilization
§ 02 — RISKS
No FDA approval; unregulated manufacturing risks including contamination and inconsistent dosing
No clinical safety data in humans from rigorous trials
Temporarily banned by WADA in 2022; banned in professional sports
Unknown long-term safety profile due to absence of comprehensive clinical studies
Potential adverse effects from unregulated non-pharmaceutical sources
§ 03 — INTERACTIONS
No interaction with your stack
VIEW STACK
CAUTION
Anticoagulants
§ 04 — SCIENCE

Preclinical studies across small rodent models consistently demonstrate that BPC-157 promotes healing in tendon, ligament, muscle, bone, skin, and gastrointestinal injuries, with no adverse effects reported across several organ systems. However, human data are extremely limited: only three pilot studies have examined BPC-157 in humans, including intra-articular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics, with no rigorous large-scale clinical trials conducted. The compound has not been approved by the FDA or other global regulatory authorities due to the absence of sufficient clinical studies. It was temporarily banned by WADA in 2022 and remains banned in professional sports. The primary safety concerns stem from unregulated manufacturing, potential contamination, and unknown clinical safety in humans.

§ 06 — SOURCES
[1]
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review
pubmed.ncbi.nlm.nih.gov ↗
[2]
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
pubmed.ncbi.nlm.nih.gov ↗
[3]
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
pubmed.ncbi.nlm.nih.gov ↗
[4]
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
pubmed.ncbi.nlm.nih.gov ↗
[5]
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
pubmed.ncbi.nlm.nih.gov ↗
[6]
BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing
pubmed.ncbi.nlm.nih.gov ↗
[7]
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
pubmed.ncbi.nlm.nih.gov ↗
[8]
Pentadecapeptide BPC 157 and the central nervous system
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT